NCI-MATCH precision medicine clinical trial releases new findings
Share

Chicago, Monday, June 4, 2018 — The National Cancer Institute’s Molecular Analysis for Therapy Choice (NCI-MATCH) trial, the largest precision medicine trial of its kind, has achieved a milestone with the release of results from several treatment arms, or sub-studies, of the trial. The new results offer findings of interest for future cancer research that could ultimately play a role in bringing targeted treatments to patients with certain gene abnormalities, regardless of their cancer type.

“NCI-MATCH represents the first attempt to systematically leverage next-generation sequencing to explore so many therapies in parallel,” said ECOG-ACRIN study chair Keith T. Flaherty, M.D., a medical oncologist at Massachusetts General Hospital Cancer Center in Boston. “By focusing our investigational effort on new biomarker-guided therapies in understudied cancer types, we have accelerated the opportunity to find signals of efficacy.”

Findings from three arms were released at this year’s American Society of Clinical Oncology (ASCO) annual meeting in Chicago, adding to findings from one arm released in November 2017. The study was co-developed by NCI, part of the National Institutes of Health, and the ECOG-ACRIN Cancer Research Group, part of the NCI-sponsored National Clinical Trials Network (NCTN). ECOG-ACRIN and NCI are co- leading the trial.

NCI-MATCH, a phase 2

read more...


Article originally posted at
www.eurekalert.org

Click here for the full story


CategoryAggregator News

© 2017 - LIFE EXTENSION ADVOCACY FOUNDATION
Privacy Policy / Terms Of Use

Powered by MMD